Direct AMPK Activation Confers Mutation‐Independent Therapeutic Benefit in Duchenne Muscular Dystrophy
These findings demonstrate that sustained, systemic activation of AMPK safely improves muscle function, metabolic health and dystrophic pathology in a mutation-independent manner. This supports the therapeutic potential of direct AMPK agonists as a disease-modifying strategy for DMD and other neuromuscular disorders.
Authors
- Andrew I. Mikhail (ORCID: https://orcid.org/0000-0001-8977-2055)
- Sean Y. Ng (ORCID: https://orcid.org/0000-0002-9238-3904)
- M. Tarnopolsky
- Vladimir Ljubicic (ORCID: https://orcid.org/0000-0002-4592-4093)
- Irena A. Rebalka (ORCID: https://orcid.org/0000-0002-4732-5473)
- Stephanie R. Mattina
- Donald Xhuti
- Sophie I. Hamstra (ORCID: https://orcid.org/0000-0001-8418-449X)
- Val A. Fajardo
- Gregory R. Steinberg
- Magda A. Lesinski
- Joshua P. Nederveen
- Thomas J. Hawke
Institutions
- Brock University (CA)
- McMaster University Medical Centre (CA)
- McMaster University (CA)
Publication Details
- Journal
- Journal of Cachexia Sarcopenia and Muscle
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/jcsm.70200
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canada Research Chairs
- Ministero dello Sviluppo Economico
- Ontario Ministry of Economic Development, Job Creation and Trade
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada